The inquest also heard that meter reader Kane Minion had skipped 32 properties on the day of his death, seven of them because of concerns about dogs. They included one next door to the Greenbank ...

An inquest into the death of a meter reader killed by dogs at a property in Logan has heard police and workplace investigators did not recommend anyone be prosecuted over the incident. Kane Minion, 42 ...

Kane Minion, 42, was working for Energy Queensland around Christmas in 2022 when he was fatally attacked at an equipment hire property at Greenbank, south of Brisbane. (Facebook) Auto news: While ...

Our columnist on notable new releases. Credit...Doeun Choi Supported by By Sarah Lyall If ever a book appeared to be designed specifically for me and my colleagues at the Book Review, it would be Dent ...

Meet Scooby, one handsome gentleman ready to charm his new family with his silly attitude and winning smile. He is a 5-year-old Pitbull and Rhodesian Ridgeback mix with black and white fur. He is a ...

Experts say there is low vaccine uptake and people are not accessing treatments. More than five years after the first cases of COVID-19 were detected in the United States, hundreds of people are still ...

This big Rhodesian Ridgeback loves to play with the 3 lb Yorkie, and it's just the cutest! Judge rules MAGA prosecutor has 'no lawful authority' and renders all her decisions 'void' Justin Bieber look ...

Kane Minion was working as a meter reader for Energy Queensland was mauled to death by dogs in 2022. Energy Queensland mandated a "no entry" policy for workers visiting properties with dogs that could ...

Regarding ultra-compact EDC, no knife hits like WESN’s aptly named Microblade. Not only is this incredibly small flipper blade built exceptionally — more like a full-sized knife than a novelty — but ...

Merck & Co – known as MSD outside of the US and Canada – and Ridgeback Biotherapeutics have initiated a late-stage study to evaluate an investigational oral antiviral COVID-19 drug in adults who are ...

Merck, known as MSD outside of the United States and Canada, announced the initiation of the phase 3 MOVe-NOW clinical trial to evaluate Lagevrio (molnupiravir), an investigational oral antiviral ...